Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report

Table 1 Laboratory data on admission

Parameter	Recorded value	Reference range
White blood cell count (× 109/L)	3.92	3.50-9.50
Red blood cell count (× 1012/L)	1.58	3.80-5.10
Hemoglobin (g/L)	54	115-150
Platelet count (× 109/L)	80	125-350
Procalcitonin (ng/mL)	1.7	< 0.1
Erythrocyte sedimentation rate (mm/h)	90	1-20
Albumin (g/L)	44.8	40.0-55.0
Calcium (mmol/L)	2.25	2.11-2.52
Phosphonium (mmol/L)	2.99	0.85-1.51
Estimated glomerular filtration rate (mL/min/1.73 m2)	7.37	-
Blood urea nitrogen (mmol/L)	11.99	2.90-7.14
Serum creatinine (µmol/L)	555.7	44.0-133.0
Ferritin (ng/mL)	4218.40	21.80-274.66
Serum iron (µmol/L)	23.1	7.8-32.2
High-density lipoprotein (mmol/L)	0.70	> 1.04
Triglyceride (mmol/L)	4.00	< 1.71
Cholesterol (mmol/L)	4.03	2.90-5.20
Low-density lipoprotein (mmol/L)	2.65	< 3.12
25 (nmol/L)	22	75-250
Glucose (mmol/L)	10.85	3.90-6.10
Hemoglobin A1c (%)	7.0	3.90-6.10
EPO concentration (mIU/mL)	53.9	4.3-29
Sucrose hemolysis test	Negative	Negative
Direct Coombs (IgG, C3) tests	Negative	Negative
Anti-EPO antibodies	Negative	Negative

EPO: Erythropoietin.

Table 2 Changes of blood parameters from baseline to 2 mo after roxadustat treatment

Laboratory test	TG (mmol/L)	CHO (mmol/L)	LDL-C (mmol/L)	HDL-C (mmol/L)	WBC (× 109/L)	PLT (× 1012/L)
Baseline	2.2	4.34	3.03	0.78	4.5	45
2 mo	1.4	2.62	1.64	0.7	4.06	81

TG: Triglyceride; CHO: Cholesterol; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoproteincholesterol; WBC: White blood cells; PLT: Platelets.